TACSTD2 and triple-negative breast carcinoma: Interestingly, 28/31 (90.3%) were stained by TrMab-6; especially, 17/31 (54.8%) were stained strongly positive by TrMab-6 (Table III), indicating that triple-negative breast cancers should be an ideal target of anti-TROP2 mAbs, including TrMab-6.